This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sultopride
- DrugBank Accession Number
- DB13273
- Background
Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics 1.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sultopride (DB13273)
- Weight
- Average: 354.47
Monoisotopic: 354.161328499 - Chemical Formula
- C17H26N2O4S
- Synonyms
- Sultopride
- Sultopridum
- Sultroprida
- External IDs
- LIN 1418
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Sultopride. Acenocoumarol The risk or severity of adverse effects can be increased when Sultopride is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Sultopride. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Sultopride. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Sultopride. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sultopride hydrochloride 8Q6926T32J 23694-17-9 IGOWMQPOGQYFFM-UHFFFAOYSA-N - International/Other Brands
- Barnetil / Topral
Categories
- ATC Codes
- N05AL02 — Sultopride
- Drug Categories
- Acids, Carbocyclic
- Amides
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Antipsychotic Agents
- Benzamides and benzamide derivatives
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Central Nervous System Depressants
- Dopamine Agents
- Dopamine Antagonists
- Moderate Risk QTc-Prolonging Agents
- Nervous System
- Neurotoxic agents
- Neurotransmitter Agents
- Psycholeptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonyl compounds
- Direct Parent
- Benzenesulfonyl compounds
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / N-alkylpyrrolidines / Sulfones / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds show 3 more
- Substituents
- Alkyl aryl ether / Amine / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonyl group / Carboximidic acid / Carboximidic acid derivative / Ether / Hydrocarbon derivative show 19 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- salicylamides (CHEBI:9356)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- AA0G3TW31W
- CAS number
- 53583-79-2
- InChI Key
- UNRHXEPDKXPRTM-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)
- IUPAC Name
- 5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide
- SMILES
- CCN1CCCC1CNC(=O)C1=CC(=CC=C1OC)S(=O)(=O)CC
References
- General References
- Inxight: Drugs - Sultopride [Link]
- External Links
- KEGG Compound
- C11708
- ChemSpider
- 5164
- BindingDB
- 86720
- 37416
- ChEBI
- 9356
- ChEMBL
- CHEMBL277945
- Wikipedia
- Sultopride
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.201 mg/mL ALOGPS logP 1.65 ALOGPS logP 1.08 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 13.22 Chemaxon pKa (Strongest Basic) 8.22 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 75.71 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 95.14 m3·mol-1 Chemaxon Polarizability 38.07 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0009000000-0c42a540860749dee71b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0bt9-2967000000-81c187eb69da03bc51f2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0009000000-cb893731ebff4f868994 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-3930000000-525af5c878ff953d534a Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0fi1-1569000000-52174f739005b1a7bc91 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-01r6-6293000000-1b63addae0d9565cafc2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 178.80779 predictedDeepCCS 1.0 (2019) [M+H]+ 181.35811 predictedDeepCCS 1.0 (2019) [M+Na]+ 189.23326 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:39 / Updated at February 21, 2021 18:54